

Mark Haas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5832474/publications.pdf>

Version: 2024-02-01

74
papers

7,224
citations

147801

31
h-index

88630

70
g-index

75
all docs

75
docs citations

75
times ranked

7616
citing authors

#	ARTICLE	IF	CITATIONS
1	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. <i>Kidney International</i> , 2009, 76, 534-545.	5.2	1,028
2	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. <i>Kidney International</i> , 2009, 76, 546-556.	5.2	892
3	Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. <i>Kidney International</i> , 2017, 91, 1014-1021.	5.2	748
4	Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. <i>Kidney International</i> , 2018, 93, 789-796.	5.2	532
5	A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. <i>Transplantation</i> , 2018, 102, 1795-1814.	1.0	479
6	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell and antibody-mediated rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2318-2331.	4.7	437
7	IgA Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 677-686.	4.5	358
8	IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. <i>New England Journal of Medicine</i> , 2017, 377, 442-453.	27.0	257
9	Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. <i>Nature Reviews Nephrology</i> , 2017, 13, 483-495.	9.6	245
10	A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 691-701.	6.1	228
11	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantation Society Working Group. <i>Transplantation</i> , 2020, 104, 911-922.	1.0	172
12	A Phase I/II Trial of the Interleukin-6 Receptor Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunglobulin in Difficult to Desensitize Patients. <i>Transplantation</i> , 2015, 99, 2356-2363.	1.0	159
13	HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1888-1897.	0.9	131
14	Early clinical experience using donor-derived cell-free DNA to detect rejection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 1663-1670.	4.7	124
15	Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. <i>American Journal of Transplantation</i> , 2020, 20, 2305-2317.	4.7	119
16	Increased Negative Impact of Donor HLA-Specific Together With Non-HLA Specific Antibodies on Graft Outcome. <i>Transplantation</i> , 2014, 97, 595-601.	1.0	105
17	The Relationship of Untreated Borderline Infiltrates by the Banff Criteria to Acute Rejection in Renal Allograft Biopsies. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1806-1814.	6.1	91
18	Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. <i>Kidney International</i> , 2017, 91, 729-737.	5.2	77

#	ARTICLE	IF	CITATIONS
19	A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients. <i>American Journal of Transplantation</i> , 2018, 18, 2955-2964.	4.7	70
20	Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. <i>Kidney International</i> , 2022, 101, 678-691.	5.2	69
21	An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 315-322.	1.6	63
22	Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization. <i>Transplantation</i> , 2015, 99, 1423-1430.	1.0	61
23	Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. <i>Kidney International</i> , 2014, 85, 779-793.	5.2	54
24	Pathology of C4d-negative antibody-mediated rejection in renal allografts. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 319-326.	1.6	52
25	The Revisited Classification of GN in SLE at 10 Years. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2938-2946.	6.1	51
26	Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1033-1044.	6.1	47
27	Donor kidney biopsies: pathology matters, and so does the pathologist. <i>Kidney International</i> , 2014, 85, 1016-1019.	5.2	46
28	Consensus definitions for glomerular lesions by light and electron microscopy: recommendations from a working group of the Renal Pathology Society. <i>Kidney International</i> , 2020, 98, 1120-1134.	5.2	41
29	The significance of C4d staining with minimal histologic abnormalities. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 21-27.	1.6	40
30	Microangiopathic Lesions in IgA Nephropathy: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 629-639.	1.9	37
31	Pathologic features of antibody-mediated rejection in renal allografts. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 264-271.	2.0	32
32	Isolated Endarteritis and Kidney Transplant Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1216-1227.	6.1	31
33	The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts. <i>American Journal of Transplantation</i> , 2018, 18, 2849-2856.	4.7	31
34	Chronic allograft nephropathy or interstitial fibrosis and tubular atrophy. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 245-250.	2.0	27
35	Donor-derived Cell-free DNA and the Prediction of BK Virus-associated Nephropathy. <i>Transplantation Direct</i> , 2020, 6, e622.	1.6	25
36	Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts. <i>Kidney International Reports</i> , 2022, 7, 720-731.	0.8	23

#	ARTICLE	IF	CITATIONS
37	Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 2666-2674.	1.0	19
38	Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 137-143.	2.0	18
39	Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 1133-1144.	4.7	18
40	A Validation of the 2018 Revision of International Society of Nephrology/Renal Pathology Society Classification for Lupus Nephritis: A Cohort Study from China. <i>American Journal of Nephrology</i> , 2020, 51, 483-492.	3.1	16
41	Morphologic Markers of Progressive Immunoglobulin A Nephropathy. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 107-113.	1.4	14
42	Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy. <i>Scientific Reports</i> , 2020, 10, 15164.	3.3	13
43	Chronic active T cell-mediated rejection is variably responsive to immunosuppressive therapy. <i>Kidney International</i> , 2021, 100, 391-400.	5.2	12
44	Donor-derived Cell-free DNA Combined With Histology Improves Prediction of Estimated Glomerular Filtration Rate Over Time in Kidney Transplant Recipients Compared With Histology Alone. <i>Transplantation Direct</i> , 2020, 6, e580.	1.6	12
45	Transplant Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1235-1237.	6.1	11
46	Loss of CD11b Exacerbates Murine Complement-Mediated Tubulointerstitial Nephritis. <i>PLoS ONE</i> , 2014, 9, e92051.	2.5	11
47	Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection. <i>Pediatric Transplantation</i> , 2022, 26, e14258.	1.0	9
48	Mesoamerican nephropathy: pathology in search of etiology. <i>Kidney International</i> , 2018, 93, 538-540.	5.2	8
49	Glomerular diseases associated with hematopoietic neoplasms: an expanding spectrum. <i>Kidney International</i> , 2011, 80, 701-703.	5.2	7
50	Overlap of ultrastructural findings in C3 glomerulonephritis and dense deposit disease. <i>Kidney International</i> , 2015, 88, 1449-1450.	5.2	7
51	Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group. <i>Kidney International</i> , 2020, 98, 310-313.	5.2	7
52	Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies. <i>Pediatric Transplantation</i> , 2017, 21, e13079.	1.0	6
53	Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregulatory Th1 Response. <i>Journal of Immunology</i> , 2015, 195, 2985-3000.	0.8	5
54	Paraprotein-associated thrombotic microangiopathy: expanding the spectrum of renal disease related to plasma cell dyscrasias. <i>Kidney International</i> , 2017, 91, 532-534.	5.2	5

#	ARTICLE	IF	CITATIONS
55	Glomerular Disease Pathology in the Era of Proteomics: From Pattern to Pathogenesis. Journal of the American Society of Nephrology: JASN, 2018, 29, 2-4.	6.1	5
56	Eculizumab as Primary Therapy for Active Antibody-mediated Rejection of Renal Allografts: A Matter of Timing, Severity, and Donor-specific Antibodies. Transplantation, 2019, 103, 2219-2220.	1.0	5
57	Molecular diagnostics in renal allograft biopsy interpretation: potential and pitfalls. Kidney International, 2014, 86, 461-464.	5.2	4
58	Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients. Pediatric Transplantation, 2017, 21, e13042.	1.0	4
59	Does the definition of chronic active T cell-mediated rejection need revisiting?. American Journal of Transplantation, 2021, 21, 1689-1690.	4.7	4
60	Simultaneous liver-kidney transplantation: shifting renal allograft gene expression from inflammation toward preservation. Kidney International, 2017, 91, 1010-1013.	5.2	3
61	Collagen type III glomerulopathy. Kidney International, 2018, 93, 1490.	5.2	3
62	Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis. Nephrology Dialysis Transplantation, 2021, 36, 1016-1022.	0.7	3
63	Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy. Kidney International Reports, 2022, 7, 78-86.	0.8	3
64	Unmasking a unique glomerular lesion. Kidney International, 2014, 86, 13-15.	5.2	2
65	Emerging Concepts and Controversies in Renal Pathology. Surgical Pathology Clinics, 2014, 7, 457-467.	1.7	2
66	Temporal Trends in the Epidemiology of Biopsy-Proven Glomerular Diseases: An Alarming Increase in Diabetic Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 556-558.	4.5	1
67	Comments on Famulski and Halloran AJT i-IFTA letter. American Journal of Transplantation, 2018, 18, 767-768.	4.7	1
68	Transplant Glomerulopathy With Glomerular C3 Deposits: Why the Worse Outcome?. Kidney International Reports, 2019, 4, 516-519.	0.8	1
69	The pathologist's view. Kidney International, 2020, 97, 1060.	5.2	1
70	Uncovering the etiology of CINAC, a complex and mysterious renal syndrome: the invaluable role of histopathology and electron microscopy. Kidney International, 2020, 97, 258-260.	5.2	1
71	Incidences of membranous nephropathy versus focal segmental glomerulosclerosis: increase in the former or decline in the latter?: Table 1. CKJ: Clinical Kidney Journal, 2013, 6, 365-367.	2.9	0
72	The Authors Reply. Kidney International, 2014, 86, 1059-1060.	5.2	0

#	ARTICLE	IF	CITATIONS
73	Towards harmony in defining and reporting glomerular diseases on kidney biopsy. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 280-286.	2.0	0
74	Cell-Mediated Glomerulonephritis Without Immune Complexes in Native Kidney Biopsies: A Report of 7 Cases. <i>American Journal of Kidney Diseases</i> , 2021, , .	1.9	0